Shield Therapeutics plc announced that its Accrufer partner for Korea, Korea Pharma Co., Ltd. (Korea Pharma) has submitted a New Drug Application (NDA) to the Korean Ministry of Food and Drug Safety (MFDS) for the review and approval of Accrufer to treat patients with iron deficiency anaemia in Korea. Pending a successful review, approval of Accrufer in Korea is anticipated in 2025. Korea Pharma's MFDS filing follows the successful completion of a pharmacokinetic (PK) study in Korea.

The PK study confirms that the absorption of iron from Accrufer is comparable between patients in Korea and the patient population enrolled in the key clinical studies supporting Accrufer® effectiveness and safety.